LYON, France--(BUSINESS WIRE)--July 31, 2006--Flamel Technologies (Nasdaq:FLML) today announced its financial results for the second quarter of 2006. Cash expenses declined during the quarter; it was the fourth consecutive sequential quarterly decline in cash expenses. The Company also announced further financial commitment from GlaxoSmithKline to expand Flamel’s manufacturing capacity in anticipation of the expected October 2006 response by the FDA with respect to Coreg CR(TM).
